Seeking Alpha

Sanofi, UCB team up to develop drugs for inflammatory diseases

  • Sanofi (SNY) is partnering with Belgium's UCB to develop anti-inflammatory small molecules that could be used "to treat a wide range of immune-mediated diseases in areas such as gastroenterology and arthritis."
  • Sanofi will make upfront and milestone payments that have the potential to surpass €100M.
  • The companies will share costs and profits on a 50-50 basis.
  • The agreement is the latest example of a major pharmaceutical company looking externally for new drugs. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: